Jones Ryan Alexander 4
4 · Kyverna Therapeutics, Inc. · Filed May 29, 2024
Insider Transaction Report
Form 4
Jones Ryan Alexander
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2024-05-28$0.73/sh+10,870$7,935→ 36,804 total - Exercise/Conversion
Common Stock
2024-05-28$0.73/sh+7,146$5,217→ 43,950 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-05-28−10,870→ 0 totalExercise: $0.73→ Common Stock (10,870 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2024-05-28−7,146→ 2,192 totalExercise: $0.73→ Common Stock (7,146 underlying)
Footnotes (2)
- [F1]25% of the original number of shares subject to the option vested on April 15, 2021, and 1/48th of the original number of shares subject to the option vested in monthly installments thereafter.
- [F2]25% of the original number of shares subject to the option vested on January 1, 2022, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.